Long-term Market Outlook Reports…

  • Global mRNA Vaccines Market to Reach $127.3 Billion by 2027. REPORT
    • The global market for mRNA Vaccines estimated at US$64.9 Billion in the year 2021, is projected to reach a revised size of US$127.3 Billion by 2027, growing at a CAGR of 11.9% over the period 2021-2027. COVID-19 mRNA Vaccines, one of the segments analyzed in the report, is projected to record a 10.6% CAGR and reach US$119 billion by the end of the analysis period.
  • The mRNA therapeutics market size was valued at USD 42.56 billion in 2021 and is expected to hit around USD 128.14 billion by 2030 and is poised to grow at a compound annual growth rate (CAGR) of 13.03% during the forecast period 2022 to 2030. REPORT
  • Annual Doses of COVID-19 Vaccines estimated at US$255 Million in the year 2020, is projected to reach US$60.7 Billion by 2025. REPORT
  • The COVID vaccine industry is expected to then grow significantly at a CAGR of over 9% and reach $47.5 billion by 2026. REPORT
  • The mRNA vaccines and therapeutics market is expected to register a CAGR of 7.15% over the forecast period. (2022-2027) REPORT
  • The Vaccine Contract Manufacturing Market is projected to register a CAGR of 12.82% during the forecast period (2022 2027). REPORT
  • The “Global Therapeutic Vaccines Market, 2022–2035” REPORT
  • Moderna said in a presentation that demand for Covid jabs in the longer term would track that of influenza vaccines and, depending on price, this could support a market worth up to $32bn annually. FT
  • Bourla told analysts on a conference call it was not unreasonable that annual sales of Pfizer’s Covid products — its vaccine Comirnaty and Paxlovid — could be worth about $15bn by 2030. But this would depend on how the virus evolved, he said. FT
Go to Top